Ebola threat expands in Guinea Africa

This deadly Ebola virus outbreak in Guinea now could expand rapidly to other parts of the world if given the chance....

Ebola: A swift, effective and bloody killer
http://www.cnn.com/2014/04/14/health/gupta-ebola-guinea/index.html

The Accelerating Medicines Partnership Announced

Ten pharmaceutical companies, seven disease-related foundations, the drug industry's main trade group and two huge federal agencies have joined together in an unusual collaboration to share information and speed up creation and approval of new drugs needed by patients.

The Accelerating Medicines Partnership, announced Tuesday by the National Institutes of Health, includes these participants:

DRUGMAKERS: AbbVie Inc., Biogen Idec Inc., Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Johnson & Johnson, Eli Lilly and Co., Merck & Co., Pfizer Inc., Sanofi SA and Takeda Pharmaceutical Co.

NONPROFIT FOUNDATIONS: Alzheimer's Association, American Diabetes Association, Foundation for the NIH, Geoffrey Beene Foundation (supports early medical research), Lupus Foundation of America, Rheumatology Research Foundation and USAgainstAlzheimer's

INDUSTRY TRADE GROUP: Pharmaceutical Research and Manufacturers of America

GOVERNMENT AGENCIES: U.S. Food and Drug Administration, National Institutes of Health

Breaking. Bird Flu in China jumps to Humans

BEIJING (Reuters) - A woman in China has died of the H10N8 strain of bird flu, the first ever reported human case of the virus, the World Health Organisation (WHO) said on Wednesday.

The 73-year-old woman died from the virus on December 6, six days after contracting the disease, the WHO said in a statement.

Bionics (the war dividend).

Great article on how Bionic technology is changing lives. We say it's due to the war dividends over the last 12 years, too bad we just didn't put the money into medical research... 

http://www.cnbc.com/id/101233869?utm_source=taboola_innovationcities

Cancer Generics $CGIX a top performing IPO

$CGIX went public in April at $10 and hits $22 almost 6mo later. Focused on DNA probes for cancer diagnostics and drug/treatment monitoring. Backing by the "Buffet" of biotech John PappaJohn, strong received  buy rating from Aegis w/ $25 target, pharma partnerships expand. (Disclosure: am early holder and long) 

Smart Phone Microscope Sees Small Virus

 Your smartphone now can see what the naked eye cannot: A single virus and bits of material less than one-thousandth of the width of a human hair.

http://scicasts.com/bio-it/1861-nanobiotechnology/6626-scientists-create-smartphone-microscope-that-can-detect-a-single-virus-nanoparticles

Sangamo's Downs Sydrome Approach

Sangamo  (SGMO) published data using their zinc finger DNA-binding protein technology to insert a gene that will essentially "silence" the extra copy of a gene that causes Downs Syndrome. The procedure provides a model for studing the basic biology of Downs syndrome, and could enable the development of drugs that can potentially rebalance the cellular processes and pathologies that are affected by the disorder.

Promising Platform for Cancer Immunotherapy


Celldex has flipped Dendreon's biological model on its head. With a goal of specifically and efficiently targeting a subset of immune cells in vivo, Celldex designed antibodies that bind to the internalization receptor (the DEC-205 receptor) on APCs, and are also tethered to the cancer antigen. The APC internalizes the antibody/antigen complex, and can then signal to T-cells to begin the assault on cancerous tissue. This method has the benefits of classical vaccines, as well as the specificity and efficiency of Dendreon's Provenge, with a fraction of the cost.

A Promising Platform for Cancer Immunotherapy - BMY, CLDX, DNDN, MRK - Foolish Blogging Network